Page 1

Press release Third quarter 2021 gsk do more feel better live longer Issued : Wednesday , 27 October 2021 , London U.K. GSK delivers strong Q3 sales of £ 9.1 billion + 5 % AER , + 10 % CER Total EPS 23.3p -7 % AER , + 3 % CER ; Adjusted EPS 36.6p + 3 % AER , + 10 % CER 2021 full year EPS guidance improved Highlights Sales growth across Pharmaceuticals , Vaccines and Consumer Healthcare driven by strong commercial execution and underlying demand • • Pharmaceuticals £ 4.4 billion + 5 % AER , + 10 % CER with growth in New and Specialty medicines + 24 % CER ; Respiratory + 33 % CER ; Immuno - inflammation + 32 % CER ex - COVID - 19 solutions ; Oncology + 34 % CER ; total HIV + 8 % CER Vaccines £ 2.2 billion + 7 % AER , + 13 % CER with Shingrix £ 502 million + 41 % CER • COVID - 19 solutions sales £ 209 million ; Xevudy £ 114 million and pandemic adjuvant £ 94 million • Consumer Healthcare £ 2.5 billion + 3 % AER , + 8 % CER ( + 10 % excluding divestments / brands under review ) Cost discipline supports delivery of EPS growth • Total Group operating margin 21.4 % . Total EPS 23.3p -7 % AER , + 3 % CER • Adjusted Group operating margin 31.7 % . Adjusted EPS 36.6p + 3 % AER , + 10 % CER . This included a contribution to growth from COVID - 19 solutions of approximately + 5 % AER , + 5 % CER in Q3 ( + 6 % AER , + 6 % CER in the nine months ) • Q3 net cash flow from operations £ 2.6 billion . Free cash flow £ 1.2 billion Continued momentum in R & D delivery and strengthening of pipeline • Additional regulatory indications approved for Nucala in respiratory and Jemperli in cancer HIV progress with FDA priority review of cabotegravir for prevention of HIV ( PDUFA action date 23 Jan 2022 ) and new collaboration on ultra long - acting integrase inhibitor Positive Phase III data on daprodustat in anaemia due to chronic kidney disease to be presented at the American Society of Nephrology meeting in Nov 2021 COVID - 19 solutions : approval in Japan for Xevudy and ongoing discussions with several governments Phase III start with SK Bioscience for adjuvanted COVID - 19 vaccine World Health Organization recommendation for broad roll - out of RTS , S malaria vaccine for children living in sub - Saharan Africa Progress on demerger to create new world - leading Consumer Healthcare company in 2022 • New UK Corporate Headquarters announced • Announcement expected of Chair Designate in Q4 2021 2021 EPS guidance improved and reconfirm 2022 outlook • Now expect 2021 Adjusted EPS to decline between -2 % to -4 % at CER excluding COVID - 19 solutions , previously mid - to - high single digit decline • Now expect 2021 Adjusted EPS contribution from COVID - 19 solutions of 7 % to 9 % at CER • Expectation for meaningful improvement in revenues and margins in 2022 reconfirmed • 2022 outlook excludes any contribution from COVID - 19 solutions Dividend of 19p declared for Q3 2021. Continue to expect 80p / share for 2021 Emma Walmsley , Chief Executive Officer , GSK said : " GSK has delivered another quarter of strong business performance , with double - digit sales growth in Pharmaceuticals and Vaccines , increased momentum in Consumer Healthcare , and continued discipline on costs . This has allowed us to improve our full - year guidance and , alongside the progress in strengthening our R & D pipeline , reinforces our confidence in the outlook for a step - change in growth and performance in 2022 and beyond . We also continue to make excellent progress towards unlocking the value of Consumer Healthcare through a successful demerger in mid - 2022 . " The Total results are presented in summary on page 2 and under ' Financial performance ' on pages 11 and 25 and Adjusted results reconciliations are presented on pages 21 , 22 , 35 and 36. Adjusted results are a non - IFRS measure that may be considered in addition to , but not as a substitute for , or superior to , information presented in accordance with IFRS . Adjusted results are defined on page 9 and £ % or AER % growth , CER % growth , free cash flow and other non - IFRS measures are defined on page 59 , COVID - 19 solutions are also defined on page 59. GSK provides guidance on an Adjusted results basis only , for the reasons set out on page 9. All expectations , guidance and targets regarding future performance and dividend payments should be read together with ' Outlook , assumptions and cautionary statements ' on pages 60 and 61 . Q3 Results summary Total and Adjusted results Issued : Wednesday , 27 October 2021 , London , U.K. Quarterly performance YTD performance Financial information 1